How do you see the future of cell and gene therapy?

drug development, , ,

Our concise outlook is the following:

Transformational Potential: Cell and gene therapies are revolutionizing how we treat diseases, promising to cure certain conditions.
They remain at the forefront of healthcare innovation.

Fast-Growing Field: These therapies are the fastest-growing therapeutics areas, with over 50 new in vivo and ex vivo gene therapy launches planned in the next few years.

Challenges and Innovation: While promising, cell and gene therapies require substantial innovation to unlock their full potential for patients. Scaling digital and analytics in discovery and R&D is part of the solution.

Market Resilience: Despite the disruptions caused by the pandemic, stakeholders, including CGT innovators, healthcare providers, and CDMOs, are optimistic that positive developments lie ahead.

Viral-Vector Therapies: Viral-vector gene therapies are here to stay, but addressing challenges and strategizing for patient access is critical for their success.

Overall, the outlook is positive, but ongoing research, regulatory advancements, and manufacturing innovations will shape the future of cell and gene therapy. 🌟

CarboHyde CEO Tamas Sohajda Presents at CPHI NA on Novel Uses of Cyclodextrins in the Pharmaceutical Industry

news, ,

CarboHyde CEO Tamas Sohajda recently delivered a compelling presentation at the CPHI North America conference, focusing on innovative applications of cyclodextrins in the pharmaceutical industry. His talk highlighted how these unique cyclic oligosaccharides can enhance drug delivery, improve solubility, and stabilize formulations, offering significant benefits to pharmaceutical development.

Cyclodextrins, known for their ability to form inclusion complexes with various molecules, have been extensively studied for their potential to revolutionize drug formulations. Sohajda’s presentation delved into recent advancements and case studies demonstrating the successful integration of cyclodextrins in new drug delivery systems. These developments promise to improve the efficacy and safety of numerous medications, addressing longstanding challenges in drug formulation and bioavailability.

The talk received considerable attention from industry professionals, underscoring CarboHyde’s leading role in pioneering the use of cyclodextrins for pharmaceutical innovation. Attendees had the opportunity to engage with Sohajda, discussing cyclodextrin research’s practical applications and future directions.

A video of the event is available on CPHI website – after a registration – for those who missed the presentation or wish to revisit the insights shared.

CPHI: Lightning Round: Excipients 4.0 – Cyclodextrins (CDs) (video) (cphi-online.com)

On Vimeo:

Dr Tamas Sohajda Lightning Round Excipients 4.0 – Cyclodextrins CDs on Vimeo

Stay tuned for more updates from CarboHyde as they continue to push the boundaries of pharmaceutical technology.

Our CEO, Tamas Sohajda, presented at CPhI North America

news,

Here are a few words from Tamás about the conference:

A few weeks ago at CPHI North America, I had the pleasure of helping the audience peek into the future of cyclodextrins by showcasing some of the applications we are working on at CarboHyde such as:
– therapeutic cyclodextrins and their development
– using cyclodextrins in vaccines
– using cyclodextrins for gene delivery

I had never spoken at CPHI before, yet it was a fascinating experience, mainly due to James Reidy’s fantastic support.

CarboHyde CEO presenting at CPHI North America

news,

We are proud to announce that our CEO, Tamas Sohajda, will deliver a talk at CPHI North America in Philadelphia in May 2024.
You can learn more about the “Exploring Excipients” session and other speakers, Denise Reaves, M.S from Jurata Thin Film, and Björn-Hendrik Peters from Bristol Myers Squibb here: 
https://www.cphi.com/northamerica/en/agenda/programme/Conference-agenda/exploring-excipients.html.

About the talk:
Explore novel applications in neurodegenerative diseases, gene therapy, and biotechnology, showcasing innovative structures, mechanisms, challenges, and results, with a focus on Alzheimer’s, Parkinson’s, rare genetic disorders, and potential expansion to longevity and infectious diseases, presenting a non-viral gene delivery platform and demonstrating CD utilization in vaccine adjuvants and biotechnological tools.